We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
- Authors
Yoshifuji, Ayumi; Toda, Masataro; Oyama, Emi; Nakayama, Tetsuo; Mise-Omata, Setsuko; Kikuchi, Kan; Yoshizawa, Mamoru; Kato, Naohiko; Wakai, Haruki; Koibuchi, Kiyoto; Morimoto, Kohkichi; Uwamino, Yoshifumi; Namkoong, Ho; Shibata, Ayako; Wakabayashi, Kaoru; Fujino, Motoko; Komatsu, Motoaki; Mochizuki, Naoki; Kondo, Norihiko; Yoshimura, Akihiko
- Abstract
Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity. Methods: Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group. Results: Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group. Conclusions: HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.
- Subjects
HUMORAL immunity; BOOSTER vaccines; COVID-19 pandemic; SARS-CoV-2; HEMODIALYSIS patients; IMMUNOLOGIC memory
- Publication
Clinical & Experimental Nephrology, 2024, Vol 28, Issue 7, p674
- ISSN
1342-1751
- Publication type
Article
- DOI
10.1007/s10157-024-02477-8